List view / Grid view
1 June 2015 | By Victoria White
AstraZeneca and Lilly have entered into a clinical trial collaboration to evaluate MEDI4736 in combination with ramucirumab in advanced solid tumours...
24 April 2015 | By Victoria White
AstraZeneca and Celgene collaborate for the development and commercialisation of MEDI4736 across a range of blood cancers, including non-Hodgkin’s lymphoma...
13 April 2015 | By Victoria White
AstraZeneca and PatientsLikeMe have signed an agreement to provide AZ with access to PatientsLikeMe’s global network to shape future medicine development...
8 April 2015 | By Victoria White
Inovio has been selected to receive a grant from DARPA to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola...
31 March 2015 | By Victoria White
AstraZeneca has joined with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project...
25 March 2015 | By Victoria White
AstraZeneca to collaborate with the HSCI to adapt a technique that creates human beta cells from stem cells to search for new treatments for diabetes...
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
27 August 2014 | By AstraZeneca
AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio...
14 August 2014 | By AstraZeneca
AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
22 July 2014 | By AstraZeneca
AstraZeneca announced that MedImmune has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies...
3 July 2014 | By MRC Technology
Initiative brings together global expertise to share compound libraries and streamline drug discovery...
12 June 2014 | By AstraZeneca
AstraZeneca announced a global licence agreement with Synairgen Plc for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma...
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
Although this target class is already heavily investigated, there are still a significant number of opportunities for discovery of novel drugs targeting additional GPCRs. In this review, scientists from AstraZeneca R&D discuss the general build-up of GPCR screening cascades for discovery of chemical leads that can be further developed into…
